Best Growth Equity Firms for Life Sciences in 2026: A Founder's Field Guide

01Best Growth Equity Firms for Life Sciences in 2026: A Founder's Field Guide

Judge a life sciences growth investor on seven things: the operating record of the partners who will do the work, how concentrated the firm is in your sector, the stage it is built to fund, the range of checks it has actually written, as the public record shows, how its partners behave in a boardroom, its reserves policy for your next round, and how long it takes to reach a term sheet. Reputation comes after all seven. A firm can be excellent and still be built for a company that is not yours.

Founders search for the best growth equity firms in life sciences in the middle of a financing process, usually a week after the first partner meeting has gone sideways. What comes back is a list sorted alphabetically, or by assets under management, which measures the size of the manager and tells you nothing about whether that manager is built for a company your size. The question you are actually asking is narrower and harder: which pool of capital is designed for a company at my stage, in my therapeutic area, with my regulatory path, and which investor has already stood where I am about to stand?

This page answers that question instead of ranking anyone. It describes how life sciences growth capital is organized, what each kind of firm is built to do, where the mid-market band sits and why it is thin, and the questions that reliably separate a partner from a check. It is arranged by type of firm, and the types are not ordered, because an ordering would be a number we invented, and you would be making a decision on it.

02Why a Ranking Is the Wrong Instrument

A ranking assumes there is one dimension worth sorting on. Capital is not sorted, it is matched. The firm that is right for a diagnostics company with a coverage problem and a working commercial team is the wrong firm for a clinical-stage therapeutics company that needs to fund a registrational trial, and both of those are wrong for a surgical robotics business that needs to build a field service organization before its installed base doubles.

Three things make the mismatch expensive rather than merely awkward. The first is check size. A fund whose smallest practical investment is larger than your whole round will either pass or push you to raise more than you need, and raising more than you need at this stage is how founders give away the ownership they were trying to protect. The second is hold period. A crossover fund underwriting a public offering inside two years is a different counterparty from an investor underwriting a five-year commercial build, even when both are friendly and both are smart. The third is governance. The investor you take is the investor who sits on your board through the next two financings, and board behavior is the part of a firm that a league table cannot show you.

So the useful exercise is not finding the best firm. It is identifying the two or three pools of capital whose design matches your company, then diligencing the individual partners inside them as carefully as they are diligencing you.

03Where Growth Equity Sits in a Life Sciences Cap Table

Growth equity occupies the band between venture capital and private equity, and in life sciences that band has a specific shape. Venture capital funds scientific and clinical risk: the molecule may not work, the algorithm may not generalize, the device may not clear. Private equity funds predictable cash flow and uses leverage to do it, which rules out most companies whose revenue is still a function of a reimbursement decision that has not happened yet. Growth equity funds the gap. The science has largely worked, there is clinical or commercial evidence, and what remains is execution risk at a scale that needs real money and almost no debt capacity.

The stage-match problem

Life sciences makes the gap wider than it is in software, because the moment a company becomes fundable by a growth investor is rarely the moment it becomes fundable by a buyout investor. A therapeutics company with positive mid-stage data has removed a great deal of scientific risk and still has no revenue. A diagnostics company with a published validation study and a CPT code has revenue and still has a payer mix that can move by thirty points in a year. Neither profile fits a classic leveraged structure, and both are past the point where a seed-stage fund can meaningfully help.

That is why the structures in this band look different. Preferred equity with participation rights, tranched investments tied to clinical or commercial milestones, revenue interests and royalty-linked instruments, and occasionally structured debt that sits beside equity rather than replacing it. A founder who walks into these conversations expecting a straightforward priced round is negotiating a structure they have not priced. The structure, not the headline valuation, is usually where the economics of the deal actually live. Our note on middle-market private equity discipline covers how that logic travels across the two asset classes.

04How Life Sciences Growth Capital Is Actually Organized

There are four recognizable pools, plus one that founders consistently forget. None of what follows is a recommendation, and none of it is exhaustive. It is a map of what each kind of investor is designed to do, so you can tell quickly whether a firm belongs on your list at all.

Healthcare-dedicated crossover funds. These firms invest across private and public markets with a single healthcare mandate, and they are often the investor who anchors a late private round and then buys into the public offering that follows. The design is excellent if your path runs through the public markets on a near horizon, and it is a poor fit if it does not, because the fund's own liquidity model assumes a market event you may not want to be forced toward.

Healthcare platforms with structured capital. These platforms pair equity with royalty-linked and structured instruments, and many of them invest across private and public healthcare companies. The advantage is that the instrument can be shaped around a company whose cash flows are lumpy and regulated. The thing to understand before you engage is that structured capital is priced on downside protection, and the price is usually paid in a scenario nobody models carefully in the first meeting.

Multi-stage crossover specialists in biopharma. These firms invest across private and public biopharma and are a regular presence on late private rounds in therapeutics. They carry deep scientific bench strength and a view of the public comparables that most private investors do not have. They are organized around the therapeutic asset. If your company's value is in a commercial system, a service model or a device installed base rather than in a molecule, you are not the shape they are built to underwrite.

Generalist global growth investors with a healthcare practice. Several large growth platforms run a healthcare vertical alongside several unrelated industries. The pattern-matching across industries is genuinely valuable, particularly on go-to-market and on scaling an organization. The question to ask is how much of the healthcare-specific judgment lives in the fund and how much is bought from advisors when a deal appears.

The pool founders forget: non-dilutive capital. Federal programs fund a meaningful amount of translational work, and the funding opportunities published by NIBIB are open to companies, not only academic labs. Non-dilutive money is slower and more administratively demanding than an equity round, and it is the cheapest capital on the board when it fits. A growth investor who has helped portfolio companies win it is telling you something real about how they work.

05The Mid-Market Band, and Where LeverVenture Sits

Set those pools side by side and a gap appears. The large healthcare-dedicated platforms and the global growth generalists both concentrate capital in big funds, and a big fund has a floor on how small a check it can write before the position stops being worth a partner's calendar. Meanwhile the venture funds that backed the company through its science are frequently unable to lead a round of the size it now needs. The company in the middle is past venture and under the floor of growth at scale, and it is often the company with the clearest evidence and the most immediate need for operating help rather than more capital.

That band is where LeverVenture works. The firm is an operator-led, mid-market growth equity investor, positioned deliberately as the bridge between venture capital and private equity in life sciences and healthcare. Operator-led is the part of that sentence that matters, and it is also the easiest claim in the industry to make without meaning it, so it is worth stating what we take it to mean: the people making the investment decision have run the functions the company is about to build, and the help arrives as work rather than as advice at a quarterly board meeting.

The mandate covers five areas of life sciences and healthcare. Biopharma and therapeutics. Diagnostics and precision medicine. Devices and robotics. Digital health and care delivery. Longevity and neuro. These are not five separate funds or five separate teams; they are one thesis about where health outcomes and enterprise value are created at the same time, which LeverVenture describes as ROI², return on investment alongside return on impact. Our longer argument for what an operating partner should actually be accountable for and for what support beyond capital looks like in practice are the fuller versions of this position.

Put on the same footing, the four pools above and the operator-led mid-market firm compare as follows. The table is not a ranking, and the order of its rows carries no meaning.

06AI Is the Accelerant, Not a Sixth Sector

Every kind of firm on this page now has something to say about artificial intelligence, and most of it is positioning. The distinction worth holding onto is structural. AI is not a sixth area beside the five above. It runs through all of them, and the interesting companies are the ones where it changes the unit economics of something that was already working: trial design and patient identification in therapeutics, image and signal interpretation in diagnostics, autonomy and telemetry in devices, triage and care navigation in delivery, biomarker discovery in longevity and neuro.

This is also why crossing sectors is the thesis rather than a complication. A company can be a healthcare company and a hard technology company at once, and the ones that are tend to be the ones worth underwriting. The regulatory consequence is specific and it is where founders get surprised: FDA has built a framework for AI-enabled device software that contemplates pre-authorized changes to a model after clearance. That turns your model-update roadmap into a regulatory document. An investor who has not read it will not diligence it, and will not have an opinion when your retraining cadence collides with your submission. We go deeper on that collision in our work on validating AI diagnostics in a real clinical workflow and on what the digital health guidance actually changed.

07Nine Questions That Separate a Partner from a Check

Use these in the second meeting, when the firm has stopped pitching and you have stopped presenting. Ask for specifics, and treat a general answer as the answer.

1. What is the smallest and largest check you have written from this fund, and what were they? Published ranges are marketing. Actual extremes tell you where you sit in the portfolio and whether you will be a priority or a rounding error.

2. Which portfolio company of yours has had a coverage or reimbursement fight, and what did you personally do during it? This question has one good answer and it includes a payer's name, a timeline and something the partner did that was inconvenient.

3. Walk me through a company where the clinical plan changed after you invested. In oncology the obvious version of this is dose optimization: FDA's Project Optimus reset what regulators expect on dose selection, and programs designed before it have had to add work. An investor who has lived through a protocol change has a different relationship to your timeline than one who has only read about it.

4. What do you believe about our regulatory path that we have not said? You are testing whether they have done independent work. A diagnostics company should expect a view on which framework governs its test at launch, given how often the status of laboratory-developed tests has moved. A therapeutics company should expect a view on whether breakthrough therapy designation is worth pursuing, and a partner who knows what the designation buys, which is intensive FDA guidance on the development program beginning as early as Phase 1, and what it does not, which is any help with the reimbursement negotiation that follows approval.

5. What does your structure look like if we miss the plan by two quarters? Ask for the downside case in writing, with the participation, ratchet and liquidation mechanics applied. Then ask what they did the last time a portfolio company missed.

6. Who from your firm is in the building in month three, and for how many days? Operating support is either staffed or it is a slide. Named people with calendars are the only version of this answer that means anything.

7. Which of your companies did not work, and may I speak with that founder? Every firm has them. The firms worth taking money from will make the introduction, and that founder's account of how the firm behaved under stress is the single most useful hour of your process.

8. How do you decide to support the next round versus let us go to market? Reserve policy is decided before a crisis and revealed during one. Ask what fraction of the fund is reserved, and what has to be true for them to lead your next round themselves.

9. What have you done in our specific area that you cannot do in someone else's? This is the band-fit question stated plainly, and it is the one that most reliably ends a conversation that should not continue.

08Reading a Track Record Without Being Sold

Exit lists are curated. There is nothing dishonest in that; curation is the format. The way to read one is to ask what each outcome required of the investor, which is a different question from whether the outcome was good.

Separate the sources of return. A company that went public into an open window returned capital because the window was open; the investor's contribution may have been real, but the exit does not demonstrate it. A company that was acquired after a reimbursement decision went its way, or after a second indication read out, or after a commercial organization was rebuilt, is evidence about operating capability. The second kind is rarer in a deck because it takes longer to explain.

Then check the follow-on behavior, which is more informative than the exits. How often did this firm lead the next round of its own companies? A firm that consistently supports its winners and quietly does not support anything else has told you its real policy, whatever the reserve slide says. Our analysis of how the venture reset changed behavior upstream of growth rounds is useful context for reading any track record assembled in the last four years, and the precision medicine landscape note covers how specialization claims should be tested in that corner of the market.

09What to Do With a Shortlist

Narrow by design before you narrow by preference. Write down your round size, the ownership you are willing to sell, the stage of your regulatory and commercial evidence, and the two functions you most need built. Then eliminate every firm whose structure cannot accommodate that, however much you liked the partner. This normally takes a list of twenty down to five or six, and it does it on criteria you can defend to your board.

Run the remaining firms through the nine questions above with the same discipline they are running diligence on you. Call the founders, including the ones whose companies did not work. Ask each firm how long its last three term sheets took from first meeting to signature, and hold it to that number. Read the downside case with your own counsel rather than the investor's description of it. And treat the whole process as what it is: you are choosing the institution that will sit across from you through the next two financings and the exit, and the decision is considerably harder to reverse than the one they are making about you.

10Frequently asked questions

What kinds of firms invest in life sciences growth rounds?

Most life sciences growth rounds are led by one of four kinds of investor: healthcare-dedicated crossover funds, healthcare platforms that pair equity with structured capital, multi-stage biopharma specialists, and global growth platforms with a healthcare practice. A thinner band sits between venture capital and the large growth funds, and it is served by operator-led, mid-market growth equity firms such as LeverVenture, whose partners have run the functions a company is about to build. Federal non-dilutive programs fund translational work alongside all of them.

What is the difference between growth equity and venture capital for a life sciences company?

Venture capital underwrites scientific and clinical risk, where the central question is whether the science works at all. Growth equity underwrites execution risk after that question has largely been answered, which usually means there is clinical or commercial evidence, a larger round, and almost no debt capacity. The practical consequence for a founder is that growth investors diligence commercial systems, regulatory strategy and management depth far harder than they diligence the underlying science.

How do I tell whether a firm's operating support is real?

Ask for names and calendars. Real operating support has specific people attached to specific functions for a specific number of days, and the firm can tell you which portfolio company those people were inside last quarter. Ask what the operators did during a reimbursement fight or a failed launch. A general answer about a platform or a network of advisors tells you the support is not staffed.

Why does nobody rank the mid-market firms?

Rankings are usually built from assets under management, because that figure is public and comparable. It sorts by the size of the manager, which is close to the opposite of what a mid-market company needs to know. A firm whose smallest practical check exceeds your entire round will score well on any such list and still be the wrong investor for you.

Does an AI component make my company a technology deal or a healthcare deal?

Both, and that is the point rather than a problem. The companies worth underwriting are generally the ones where a model changes the economics of something already working clinically or commercially. What does change is the diligence: an AI-enabled device turns the model-update roadmap into a regulatory document, so the investor needs an opinion on retraining cadence, change control and validation, not only on model performance.

Nothing in this piece is investment, legal, tax or accounting advice, and nothing in it is an offer to sell any security. Fund I is offered only as stated on the Fund I page.